Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
Rattachement africain : hr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background. Although today it is almost preventable, cervical cancer still represents a significant cancer burden, especially in some developing parts of the world. Since the introduction of bevacizumab in the first-line treatment of metastatic disease, improvements of the outcomes were noted. However, results from randomized controlled trials are often hard to recreate in the real-world setting. Objective. To assess the real-world efficacy and safety of bevacizumab as a first-line treatment of advanced cervical cancer. Methods. We conducted a retrospective cohort study on the total population of Croatian patients diagnosed with metastatic cervical cancer from 2016 to 2019 who were treated with bevacizumab in combination with cisplatin and paclitaxel (TCB) in the first line. The comparison group was the consecutive sample of patients treated with chemotherapy alone. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, incidence of adverse events, and the proportion of treatment discontinuation. Results. We enrolled 67 patients treated with TCB and a control group of 62 patients treated with chemotherapy alone. The TCB cohort had significantly longer unadjusted OS with a median of 27.0 (95% CI 18.5; not calculable) months, compared to 15.5 (10.7; 30.1) months in the chemotherapy-alone cohort. Adjusted OS was not significantly different. PFS was significantly longer for the TCB cohort, with a median of 10.6 (95% CI 8.5; 15.4) months, than for the chemotherapy-alone cohort, with a median of 5.4 (95% CI 3.9; 9.1) months, even after adjustment for baseline covariates (HRadjusted = 0.60; 95% CI 0.39; 0.94; p = 0.027 ; false discovery rate <5%). Conclusions. In a real-world setting, TCB as a first-line treatment of metastatic cervical cancer was associated with longer PFS, better objective disease control rate, and acceptable toxicity profile in comparison to chemotherapy alone. These results may indicate its utility and potential applicability in other parts of the developing world.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
- Date Crossref
- 05/08/2021
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Split pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Centre Zagreb pays non établi dans la noticeÉtablissement de santé
-
University of Rijeka pays non établi dans la noticeUniversité ou école supérieure
-
University of Osijek pays non établi dans la noticeUniversité ou école supérieure
-
Psychiatric Hospital Sveti Ivan pays non établi dans la noticeÉtablissement de santé
-
University Hospital Center Split Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Zagreb Department of Gynecologic Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Rijeka Department of Radiotherapy and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital for Tumors Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Center Osijek Department of Radiotherapy Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Psychiatric Hospital “Sveti Ivan” Research Unit “Dr. Mirko Grmek” pays non établi dans la noticeUniversité ou école supérieure
University of Split, University Hospital Centre Zagreb et University of Rijeka, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.